Lv1
50 积分 2026-05-22 加入
Expert consensus on the application and management of therapeutic drugs for atopic dermatitis （2024）
28天前
已完结
特应性皮炎及其共病的多学科全病程管理专家共识（2026版）
28天前
已完结
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
1个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
1个月前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
